Prosecution Insights
Last updated: November 12, 2026
Application No. 18/711,415

METHOD OF CARDIOPROTECTION

Non-Final OA §112
Filed
May 17, 2024
Priority
Nov 19, 2021 — AU 2021903734 +2 more
Examiner
WILLIS, DOUGLAS M
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Race Oncology Ltd.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
1504 granted / 1825 resolved
+22.4% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
66 currently pending
Career history
1874
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The inventor or joint inventor should note that the instant invention, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-5, 7, 8, 10-13, 15 and 30 are pending in the instant invention. According to the Listing of Claims, filed September 15, 2026, claims 1, 3, 7 and 15 were amended, claims 6, 9, 14 and 16-29 were cancelled and claim 30 was added. Status of Priority This invention is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/AU2022/051380, filed November 18, 2022, which claims priority under 35 U.S.C. § 119(a-d) to: a) AU 2022901827, filed June 30, 2022; and b) AU 2021903734, filed November 19, 2021. Restrictions / Election of Species PNG media_image1.png 329 220 media_image1.png Greyscale The inventor’s or joint inventor’s provisional election of the following, without traverse, in the reply filed on September 15, 2026, is acknowledged: a) Group VII - claims 1, 2, 7, 8, 13, 15 and 30; and b) cardioprotective agent comprising (i) bisantrene, or a pharmaceutically acceptable salt thereof; and (ii) a chemotherapeutic anthra-cycline cardiotoxic agent selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin, or a pharmaceutically acceptable salt thereof - Figures 3, 8 and 10A, cardioprotective agent comprising (i) bisantrene, shown to the left above; and (ii) the chemotherapeutic anthracycline cardiotoxic agent, doxorubicin. Claims 1, 2, 7, 8, 13, 15 and 30 read on the elected species. Affirmation of this election must be made by the inventor or joint inventor in replying to this Office action. Similarly, the inventor or joint inventor should further note that the requirement is still deemed proper and is therefore made FINAL. Likewise, the inventor or joint inventor should further note that the elected species, shown to the left above, was found to be free of the prior art. Moreover, the inventor or joint inventor should further note that claims 3, 5 and 10-12 were withdrawn from further consideration, pursuant to 37 CFR 1.142(b), as being drawn to a nonelected or cancelled invention, there being no allowable generic or linking claim. Thus, a first Office action and prosecution on the merits of claims 1, 2, 7, 8, 13, 15 and 30 is contained within. Specification Objection - Disclosure The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the inventor’s or joint inventor’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility invention should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase Not Applicable should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC. (f) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art (including information disclosed under 37 CFR 1.97 and 1.98). (g) BRIEF SUMMARY OF THE INVENTION. (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (i) DETAILED DESCRIPTION OF THE INVENTION. (j) CLAIM OR CLAIMS (commencing on a separate sheet). (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (l) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825). The inventor or joint inventor is advised to format the specification according to 37 CFR 1.77(b) above and 37 CFR 1.77(c). Revisions should particularly include and/or address: a) section headings (b-i), where applicable; and b) bold-type, underline, and/or upper case formatting. Appropriate correction may be required. Specification Objection - Title The inventor or joint inventor is reminded of the proper content of the title of the invention. The title of the invention should be brief, but technically accurate and descriptive and should contain fewer than 500 characters. See 37 CFR 1.72(a) and MPEP § 606. The title of the invention is not technically accurate and descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. In the revised title, the examiner suggests additionally identifying bisantrene. The following title is suggested: METHOD FOR CARDIOPROTECTION COMPRISING ADMINISTERING BISANTRENE. Appropriate correction is required. Specification Objection - Abstract The inventor or joint inventor is reminded of the proper content of an abstract of the disclosure. With regard particularly to chemical patents, for compounds or compositions, the general nature of the compound or composition should be given as well as the use thereof, e.g., The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics. Exemplification of a species could be illustrative of members of the class. For processes, the reactions, reagents and process conditions should be stated, generally illustrated by a single example, unless variations are necessary. See MPEP § 608.01(b), Section B. The abstract of the disclosure is objected to because it fails to exemplify any members or formulae illustrative of its class. Correction is required. See MPEP § 608.01(b). The examiner suggests incorporating the structure of bisantrene into the abstract, to overcome this objection. Claim Objections Claim 1 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a) and comply with the Requirement for Restriction/Election of Species, mailed on July 15, 2026, the existing recitation should be replaced with the following recitation: A method for reducing drug-induced cardiotoxicity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a cardioprotective agent comprising bisantrene of the following formula: PNG media_image2.png 437 296 media_image2.png Greyscale , or a pharmaceutically acceptable salt thereof; wherein the drug-induced cardiotoxicity is caused by a cardiotoxic chemotherapeutic agent comprising an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin, or a pharmaceutically acceptable salt thereof. Appropriate correction is required. See MPEP § 2173.02. Claim 2 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b), 35 U.S.C. § 112(d) and comply with the Requirement for Restriction/Election of Species, mailed on July 15, 2026, the existing recitation should be replaced with the following recitation: The method of claim 1, wherein the method comprises administering to the subject a therapeutically effective amount of the cardioprotective agent comprising bisantrene prior to, simultaneously with, or after administration of a cardiotoxic agent comprising an anthracycline to the subject. Appropriate correction is required. See MPEP § 2173.02. Claim 7 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The method of claim 1, wherein the drug-induced cardiotoxicity is caused by a cardiotoxic chemotherapeutic agent comprising an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Appropriate correction is required. See MPEP § 2173.02. Claim 8 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The method of claim 7, wherein the drug-induced cardiotoxicity is caused by a cardiotoxic chemotherapeutic agent comprising an anthracycline selected from the group consisting of daunorubicin, doxorubicin, and epirubicin. Appropriate correction is required. See MPEP § 2173.02. Claim 13 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The method of claim 1, wherein the method comprises administering to the subject the cardioprotective agent comprising bisantrene in an amount in the range of from 5 mg/m2/week to 100 mg/m2/week over a period of four weeks. Appropriate correction is required. See MPEP § 2173.02. Claim 15 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The method of claim 1, wherein: (a) the method comprises administering to the subject the cardioprotective agent comprising bisantrene, or a pharmaceutically acceptable salt thereof, in an amount in the range of from 5 mg/m2/week to 50 mg/m2/week over a period of four weeks; and (b) the drug-induced cardiotoxicity is caused by a cardiotoxic chemotherapeutic agent comprising an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Appropriate correction is required. See MPEP § 2173.02. Claim 30 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The method of claim 15, wherein the drug-induced cardiotoxicity is caused by a cardiotoxic chemotherapeutic agent comprising an anthracycline selected from the group consisting of daunorubicin, doxorubicin, and epirubicin. Appropriate correction is required. See MPEP § 2173.02. Claim Rejections - 35 U.S.C. § 112(b) The following is a quotation of the second paragraph of 35 U.S.C. § 112: (b) CONCLUSION. The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or joint inventor regards as the invention. Claim 13 is rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention. The inventor or joint inventor should note that the term, about, is a relative term which renders the claim indefinite. The term, about, is not defined by the claim, the specification does not provide an adequate standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the invention. The specification fails to adequately define the term, about. Similarly, the meaning of a term cannot depend on the unrestrained, subjective opinion of the inventor or joint inventor practicing the invention. Moreover, neither the specification, nor the claim, explicitly limits the invention to any specifically disclosed or recited embodiments. Consequently, the method for reducing drug-induced cardiotoxicity caused by a cardiotoxic agent in a subject, the method comprising administering… a cardioprotective agent comprising bisantrene has been rendered indefinite by the use of the term, about. {See Ortho-McNeil Pharm., Inc. v. Caraco Pharm. Labs., Ltd., 476 F.3d 1321, 1326, 81 USPQ2d 1427, 1432 (Fed. Cir.2007); W. L. Gore & Associates, Inc. v. Garlock, Inc., 721 F.2d 1540, 220 USPQ 303 (Fed. Cir. 1983); Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991); and MPEP § 2173.05(b)}. The examiner suggests amending the claim, particularly as stated in the section above entitled Claim Objections, to overcome this rejection. Claims 15 and 30 are rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention. The inventor or joint inventor should note that the term, about, in claim 15, is a relative term which renders the claim indefinite. The term, about, is not defined by the claim, the specification does not provide an adequate standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the invention. The specification fails to adequately define the term, about. Similarly, the meaning of a term cannot depend on the unrestrained, subjective opinion of the inventor or joint inventor practicing the invention. Moreover, neither the specification, nor the claim, explicitly limits the invention to any specifically disclosed or recited embodiments. Consequently, the method for reducing drug-induced cardiotoxicity caused by a cardiotoxic agent in a subject, the method comprising administering… a cardioprotective agent comprising bisantrene has been rendered indefinite by the use of the term, about. {See Ortho-McNeil Pharm., Inc. v. Caraco Pharm. Labs., Ltd., 476 F.3d 1321, 1326, 81 USPQ2d 1427, 1432 (Fed. Cir.2007); W. L. Gore & Associates, Inc. v. Garlock, Inc., 721 F.2d 1540, 220 USPQ 303 (Fed. Cir. 1983); Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991); and MPEP § 2173.05(b)}. Moreover, the inventor or joint inventor should further note that [C]laims which depend from indefinite claims are also indefinite. {See Ex parte Cordova, 10 USPQ 2d 1949, 1952 (PTO Bd. App. 1989)}. The examiner suggests amending the claims, particularly as stated in the section above entitled Claim Objections, to overcome this rejection. Allowable Subject Matter No claims are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOUGLAS M. WILLIS, whose telephone number is 571-270-5757. The examiner may normally be reached on Monday thru Thursday from 8:00-6:00 EST. The examiner is also available on alternate Fridays. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Jeffrey Murray, may be reached on 571-272-9023. The fax phone number for the organization where this invention or proceeding is assigned is 571-273-8300. Information regarding the status of an invention may be obtained from Patent Center. For more information about Patent Center, see https://www.uspto.gov/patents/apply/patent-center. Should you have questions on access to Patent Center, contact the Patent Electronic Business Center (PEBC) at 866-217-9197 (toll-free) or ebc@uspto.gov. /DOUGLAS M WILLIS/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 17, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788697
TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS
4y 0m to grant Granted Nov 10, 2026
Patent 12778965
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
3y 11m to grant Granted Nov 03, 2026
Patent 12780838
MTORC1 MODULATORS AND USES THEREOF
3y 8m to grant Granted Nov 03, 2026
Patent 12774296
PYRIDINE-2-AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
3y 4m to grant Granted Oct 27, 2026
Patent 12767660
CONDENSED HETEROCYCLIC COMPOUND
4y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
99%
With Interview (+19.8%)
Low
PTA Risk
Based on 1825 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month